Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Arv-471
2. Arv-471 (protac)
3. Wc1u3r1ymi
4. 2229711-68-4
5. Arv471
6. (s)-3-(5-(4-((1-(4-(rel-(1r,2s)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
7. 2614417-52-4
8. Vepdegestrant [inn]
9. Starbld0006985
10. Unii-wc1u3r1ymi
11. Arv 471
12. Arv 471 [who-dd]
13. Chembl5095210
14. Schembl20211870
15. Akos040757430
16. Ms-31245
17. Hy-138642
18. Cs-0159885
19. En300-37105519
20. (2(1)r,2(2)s,8(3)s)-2-hydroxy-2(1),2(2),2(3),2-tetrahydro-7(5,2)-isoindola-6(1,4)-piperazina-4(1,4),8(3)-dipiperidina-2(2,1)-naphthalena-1(1),3(1,4)-dibenzenaoctaphane-7(1),8(2),8(7(3)h)-trione
21. (3s)-3-(5-{4-[(1-{4-[(1r,2s)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenyl}piperidin-4-yl)methyl]piperazin-1-yl}-1-oxo-2,3-dihydro-1h-isoindol-2-yl)piperidine-2,6-dione
22. (s)-3-(5-(4-((1-(4-((1r,2s)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
23. 2,6-piperidinedione, 3-(1,3-dihydro-1-oxo-5-(4-((1-(4-((1r,2s)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl)phenyl)-4-piperidinyl)methyl)-1-piperazinyl)-2h-isoindol-2-yl)-, (3s)-
Molecular Weight | 723.9 g/mol |
---|---|
Molecular Formula | C45H49N5O4 |
XLogP3 | 6.4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 7 |
Exact Mass | g/mol |
Monoisotopic Mass | g/mol |
Topological Polar Surface Area | 96.4 |
Heavy Atom Count | 54 |
Formal Charge | 0 |
Complexity | 1310 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Details:
ARV-471 (vepdegestrant) is an investigational PROTAC protein degrader designed to target and degrade the estrogen receptor. It is being evaluated for the treatment of ER+/HER2- breast cancer.
Lead Product(s): Vepdegestrant
Therapeutic Area: Oncology Brand Name: ARV-471
Study Phase: Phase IIIProduct Type: PROTACs
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 11, 2025
Lead Product(s) : Vepdegestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
Details : ARV-471 (vepdegestrant) is an investigational PROTAC protein degrader designed to target and degrade the estrogen receptor. It is being evaluated for the treatment of ER+/HER2- breast cancer.
Product Name : ARV-471
Product Type : PROTACs
Upfront Cash : Inapplicable
March 11, 2025
Details:
ARV-471 (vepdegestrant) is an investigational PROTAC protein degrader designed to target and degrade the estrogen receptor. It is being evaluated for the treatment of ER+/HER2- breast cancer.
Lead Product(s): Vepdegestrant,Abemaciclib
Therapeutic Area: Oncology Brand Name: ARV-471
Study Phase: Phase I/ Phase IIProduct Type: PROTACs
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 10, 2024
Lead Product(s) : Vepdegestrant,Abemaciclib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Benefit
Details : ARV-471 (vepdegestrant) is an investigational PROTAC protein degrader designed to target and degrade the estrogen receptor. It is being evaluated for the treatment of ER+/HER2- breast cancer.
Product Name : ARV-471
Product Type : PROTACs
Upfront Cash : Inapplicable
December 10, 2024
Details:
ARV-471 (vepdegestrant) is an oral bioavailable PROTAC protein degrader designed to target & degrade the estrogen receptor, currently in phase 3 trials for ER+/HER2- breast cancer treatment.
Lead Product(s): Vepdegestrant
Therapeutic Area: Oncology Brand Name: ARV-471
Study Phase: Phase IIIProduct Type: PROTACs
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 02, 2024
Lead Product(s) : Vepdegestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Arvinas and Pfizer’s Vepdegestrant Receives Fda Fast Track Designation for Treatment
Details : ARV-471 (vepdegestrant) is an oral bioavailable PROTAC protein degrader designed to target & degrade the estrogen receptor, currently in phase 3 trials for ER+/HER2- breast cancer treatment.
Product Name : ARV-471
Product Type : PROTACs
Upfront Cash : Inapplicable
June 02, 2024
Details:
ARV-471 (vepdegestrant) is an investigational PROTAC protein degrader designed to target and degrade the estrogen receptor. It is being evaluated for the treatment of ER+/HER2- breast cancer.
Lead Product(s): Vepdegestrant,Palbociclib
Therapeutic Area: Oncology Brand Name: ARV-471
Study Phase: Phase I/ Phase IIProduct Type: PROTACs
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 16, 2024
Lead Product(s) : Vepdegestrant,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Arvinas and Pfizer Updated Clinical Data from Phase 1b of Vepdegestrant with Palbociclib
Details : ARV-471 (vepdegestrant) is an investigational PROTAC protein degrader designed to target and degrade the estrogen receptor. It is being evaluated for the treatment of ER+/HER2- breast cancer.
Product Name : ARV-471
Product Type : PROTACs
Upfront Cash : Inapplicable
May 16, 2024
Details:
CT7001 (samuraciclib) is a first-in-class oral CDK7 inhibitor evaluated with ARV-471 (vepdegestrant) for ER+, HER2- metastatic breast cancer treatment.
Lead Product(s): Samuraciclib,Vepdegestrant
Therapeutic Area: Oncology Brand Name: CT7001
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 14, 2024
Lead Product(s) : Samuraciclib,Vepdegestrant
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Carrick Doses First Patient in Phase 1b/2 Trial of Samuraciclib in Breast Cancer
Details : CT7001 (samuraciclib) is a first-in-class oral CDK7 inhibitor evaluated with ARV-471 (vepdegestrant) for ER+, HER2- metastatic breast cancer treatment.
Product Name : CT7001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2024
Details:
Arvinas expects to use net proceeds to advance its clinical development programs and preclinical pipeline, including ARV-471 (vepdegestrant), an investigational orally bioavailable PROTAC® protein degrader.
Lead Product(s): Vepdegestrant
Therapeutic Area: Oncology Brand Name: ARV-471
Study Phase: Phase IIIProduct Type: PROTACs
Sponsor: BofA Securities
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 27, 2023
Lead Product(s) : Vepdegestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : BofA Securities
Deal Size : $350.0 million
Deal Type : Private Placement
Arvinas Announces Oversubscribed $350 Million Private Placement
Details : Arvinas expects to use net proceeds to advance its clinical development programs and preclinical pipeline, including ARV-471 (vepdegestrant), an investigational orally bioavailable PROTAC® protein degrader.
Product Name : ARV-471
Product Type : PROTACs
Upfront Cash : Undisclosed
November 27, 2023
Details:
ARV-471 (vepdegestrant) is an investigational, orally bioavailable PROTAC® protein degrader designed to specifically target and degrade the estrogen receptor for the treatment of patients with early and locally advanced breast cancer.
Lead Product(s): Vepdegestrant
Therapeutic Area: Oncology Brand Name: ARV-471
Study Phase: Phase IIIProduct Type: PROTACs
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 31, 2023
Lead Product(s) : Vepdegestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ARV-471 (vepdegestrant) is an investigational, orally bioavailable PROTAC® protein degrader designed to specifically target and degrade the estrogen receptor for the treatment of patients with early and locally advanced breast cancer.
Product Name : ARV-471
Product Type : PROTACs
Upfront Cash : Inapplicable
July 31, 2023
Details:
ARV-471 is an investigational, orally-bioavailable PROTAC® protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
Lead Product(s): Vepdegestrant,Palbociclib
Therapeutic Area: Oncology Brand Name: ARV-471
Study Phase: Phase I/ Phase IIProduct Type: PROTACs
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 22, 2022
Lead Product(s) : Vepdegestrant,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ARV-471 is an investigational, orally-bioavailable PROTAC® protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
Product Name : ARV-471
Product Type : PROTACs
Upfront Cash : Inapplicable
November 22, 2022
Details:
The results showed ARV-471 has the potential to become a first-in-category treatment, and a new standard of care, for ER+/HER2- breast cancer patients and showed clinical benefits including tumor shrinkage and good tolerability.
Lead Product(s): Vepdegestrant,Palbociclib
Therapeutic Area: Oncology Brand Name: ARV-471
Study Phase: Phase I/ Phase IIProduct Type: PROTACs
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 10, 2021
Lead Product(s) : Vepdegestrant,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging...
Details : The results showed ARV-471 has the potential to become a first-in-category treatment, and a new standard of care, for ER+/HER2- breast cancer patients and showed clinical benefits including tumor shrinkage and good tolerability.
Product Name : ARV-471
Product Type : PROTACs
Upfront Cash : Inapplicable
October 10, 2021
Details:
Collaboration combines Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast oncology therapeutics. ARV-471 is currently in Phase 2 trial for patients with locally advanced/metastatic ER+/HER2- breast cancer.
Lead Product(s): Vepdegestrant,Palbociclib
Therapeutic Area: Oncology Brand Name: ARV-471
Study Phase: Phase I/ Phase IIProduct Type: PROTACs
Sponsor: Pfizer Inc
Deal Size: $2,050.0 million Upfront Cash: $650.0 million
Deal Type: Collaboration July 22, 2021
Lead Product(s) : Vepdegestrant,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : $2,050.0 million
Deal Type : Collaboration
Arvinas & Pfizer Global Collaboration to Develop and Commercialize PROTAC®
Details : Collaboration combines Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast oncology therapeutics. ARV-471 is currently in Phase 2 trial for patients with locally advanced/metastatic ER+/H...
Product Name : ARV-471
Product Type : PROTACs
Upfront Cash : $650.0 million
July 22, 2021
ABOUT THIS PAGE